title: Serum bone biomarkers and oral/systemic bone loss in humans.
abstract: We recently reported that subantimicrobial-dose doxycycline (SDD) significantly reduced serum bone-resorption biomarkers in subgroups of post-menopausal women. We hypothesize that changes in serum bone biomarkers are associated not only with systemic bone mineral density (BMD) changes, but also with alveolar bone changes over time. One hundred twenty-eight eligible post-menopausal women with periodontitis and systemic osteopenia were randomly assigned to receive SDD or placebo tablets twice daily for two years, adjunctive to periodontal maintenance. Sera were analyzed for bone biomarkers. As expected, two-year changes in a serum bone biomarker were significantly associated with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025). Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of type I collagen (ICTP; bone-resorption biomarker) were also significantly associated with alveolar bone density loss (p < 0.0001) and alveolar bone height loss (p = 0.0008), respectively. Thus, we have shown that serum bone biomarkers are associated with not only systemic BMD loss, but with alveolar bone loss as well.
  
  
  BACKGROUND
  Protocol registered at ClinicalTrials.gov, NCT00066027.
authors.affiliation: Department of Surgical Specialties, University of Nebraska Medical Center College of Dentistry, Lincoln, NE 68583-0740, USA. jbpayne@unmc.edu
authors.forename: J B
authors.initials: JB
authors.lastname: Payne
authors.forename: J A
authors.initials: JA
authors.lastname: Stoner
authors.forename: H-M
authors.initials: HM
authors.lastname: Lee
authors.forename: P V
authors.initials: PV
authors.lastname: Nummikoski
authors.forename: R A
authors.initials: RA
authors.lastname: Reinhardt
authors.forename: L M
authors.initials: LM
authors.lastname: Golub
mesh_terms: D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D016301:Alveolar Bone Loss / Q000097:blood* / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D002648:Child; D024042:Collagen Type I / Q000097:blood*; D004311:Double-Blind Method; D004318:Doxycycline / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016014:Linear Models; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood*; D010455:Peptides / Q000097:blood*
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; C548267:ALPL protein, human; D000469:Alkaline Phosphatase; D004318:Doxycycline